Risky business: Re-evaluating participant risk in biobanking

Human Tissue Research: A European Perspective on the Ethical and Legal Challenges

Volumn , Issue , 2011, Pages

  Hoppe, Nils ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

Biobanking; Consent; Ethics; Genetic data; Law; Medical data; Risk

Indexed keywords

EID: 84922760872     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780199587551.003.0004     Document Type: Chapter

References (23)

1. Arning, M., Forgó, N., and Krügel, T. (2006). Datenschutzrechtliche Aspekte der Forschung mit genetischen Daten [Data privacy: legal aspects of research with genetic data]. Datenschutz und Datensicherheit, 30, 700-5.
2. Beauchamp, T.L. and Childress, J.F. (2001). Principles of biomedical ethics. New York: Oxford University Press.
3. Beck, U. (1986). Risikogesellschaft-Auf dem Weg in eine andere Moderne [A society of risk-on ist way to a new modern age]. Frankfurt: Suhrkamp.
4. Bentley, J.P. and Thacker, P.G. (2004). The influence of risk and monetary payment on the research participation decision making process. Journal of Medical Ethics, 30, 293-8.
5. Bonß, W. (1995). Vom Risiko: Unsicherheit und Ungewissheit in der Moderne [Of risk: insecurity and uncertainty in the modern age]. Hamburg: Hamburger Edition.
6. Cambon-Thomsen, A. (2004). The social and ethical issues of post-genomic human biobanks. Nature Reviews Genetics, 5, 866-73.
7. Campbell, A.V. (2006). The ethical challenges of biobanks: safeguarding altruism and trust. In S.A.M. MacLean (ed.), First do no harm: law, ethics and healthcare. Aldershot: Ashgate.
8. Crocco, A. and D'Elia, D. (2007). Adverse reactions during voluntary donation of blood and/or blood components. A statistical epidemiological study. Blood Transfusion, 5, 143-52.
9. Dressler, L.G. (2009). Biobanking and disclosure or research results: addressing the tension between professional boundaries and moral intuition. In J.H. Solbakk, S. Holm, and B. Hofmann (eds), The ethics of research biobanking. Dordrecht: Springer.
10. Eriksson, S. and Helgesson, G. (2005). Potential harms, anonymization, and the right to withdraw consent to biobank research. European Journal of Human Genetics, 13, 1071-6.
11. Hendrick, J. (2001). Legal Aspects of Clinical Ethics Committees. Journal of Medical Ethics, 27, i50-i53.
12. Hernandez, R. et al. (2009). Harmonisation of ethics committees' practice in 10 European countries. Journal of Medical Ethics, 35, 696-700.
13. Hoppe, N. (2009). Bioequity-property and the human body. Farnham: Ashgate.
14. Luhmann, N. (1991). Soziologie des Risikos [A sociology of risk]. Berlin: de Gruyter.
15. Nationaler Ethikrat. (2004). Biobanken für die Forschung [Biobanks for research]. Berlin: Nationaler Ethikrat.
16. Radcliffe Richards, J. (2003). Commentary: an ethical market in human organs. Journal of Medical Ethics, 29, 139-40.
17. SCCNFP (Scientific Committee on Cosmetic Products and Non-Food Products Intended for Consumers) (2004). Recommended mutagenicity/genotoxicity tests for the safety testing of cosmetic ingredients to be included in the annexes to Council Directive 76/768/EEC. (SCCNFP/0755/03). Available at: (accessed 8 December 2009).
18. Shrader-Frechette, K. (1998). Risk. In E. Craig (ed.), Routledge Encyclopedia of Philosophy, Vol. 8, pp. 331-4. London: Routledge.
19. Simpson, J. and Weiner, E. (ed.) (1998). Oxford English Dictionary. (2nd edn). Oxford: Oxford University Press.
20. Stauch, M.S. (2001). Risk and remoteness of damage in negligence. Modern Law Review, 64, 191-214.
21. UK Biobank (2009). UK Biobank information leaflet. Available at: (accessed 9 December 2009).
22. van Luijn, H.E.M., Aaronson, N.K., Keus, R.B., and Musschenga, A.W. (2006). The evaluation of risks and benefits of phase II cancer clinical trials by institutional review board (IRB) members: a case study. Journal of Medical Ethics, 32, 170-6.
23. WMA (World Medical Association) (2008). Declaration of Helsinki. Available at: (accessed 8 December 2009).